secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-06-08T12:30:18+00:00
Accession:  0001493152-26-027641
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.03, 3.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics enters debt-to-equity exchange; receives Nasdaq bid price deficiency notice
--------------------------------------------------------------------------------

- Exchange agreement to convert up to $4.5M of Streeterville debt into non-convertible preferred and common stock, contingent on equity financings of at least $2.6M (first tranche) by June 15, 2026.
- Streeterville suspends monthly principal redemptions until Sept 15, 2026; reduces monthly cap to $225K; extends note maturity to June 10, 2027.
- Vivos issued V-Co Investors 4 LLC a $5M convertible note (initial $500K draw) to support proposed $5.5M equity financing expected by June 30, 2026.
- Nasdaq notified Vivos on June 5, 2026, of non-compliance with $1.00 minimum bid price; 180-day cure period ends Dec 2, 2026.
- Company also fails Nasdaq's $2.4M minimum stockholders' equity requirement; plans to cure via exchange agreement and equity raise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/0001493152-26-027641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer